Board of Directors
Calvin Stiller, OC, OO, MD
Dr. Calvin Stiller is a lifelong innovator whose work encompasses science, business and public service. As a scientist, Stiller was principal investigator on the Canadian multi-centre study that established the effectiveness of Cyclosporine in transplantation, which led to its worldwide use as first-line therapy for transplant rejection. He has published 265 scientific and medical papers, co-edited five books and is the author of Lifegifts, a book about organ transplantation.
In 1985 Stiller established the Multi-Organ Transplant Service in London and served as its chief for over a decade. He has been president of the Canadian Society of Nephrology and co-founded the MaRS Centre, the J. Allyn Taylor International Prize in Medicine and the Canadian Medical Hall of Fame. Dr. Stiller is also an entrepreneur and businessperson. He founded two firms that eventually employed 4,000 people in health care and technology services, which were later sold and taken public. He established four venture capital funds to invest in innovation, including the largest life sciences fund in Canada. He has also founded three companies that have provided seed funding for 50 technologies and created over a quarter of a billion dollars in economic activity.
Stiller received his medical degree from the University of Saskatchewan in 1965 and his fellowship in the Royal College of Physicians and Surgeons of Canada (FRCPC) in 1972 following seven years of post-graduate studies in Edmonton and London, Ontario. He is a member of the Order of Ontario and officer of the Order of Canada. He is the recipient of four Honorary Degrees and the Canada Wightman Gairdner Award.
Mr. Peter Fullerton is with Grant Thornton, a leading Canadian accounting, auditing and business advisory firm. He has a strong audit background that crosses several sectors.
Fullerton is very involved in community organizations. He is the convenor of the board of governors of Knox College, University of Toronto. He is the former chair and board member of Holland Bloorview Kids Rehabilitation Hospital, and currently is a member of the Hospital’s Business and Audit Committee. He is a board member of the Ontario Tourism Marketing Partnership Corporation and the Huron University College Foundation and is a member of The Presbyterian Church in Canada Audit Committee.
Fullerton received a BA from Huron University College, University of Western Ontario. He has been a chartered accountant since 1974 and became a Fellow of the Institute of Chartered Accountants of Ontario in 2003. He is a member of the Institute of Corporate Directors.
Robert N. Klein is currently the President of Klein Financial Corporation, a company that designs and implements innovative solutions for affordable housing mortgage financing. He served as the author and Chairman of California’s Proposition 71, the $3 billion “California Stem Cell Research and Cures” Ballot Initiative which succeeded in establishing the California Institute for Regenerative Medicine (CIRM).
The focus of Mr. Klein’s public service and charitable commitments has been on medical research and affordable housing. In 2002, Mr. Klein was a principal negotiator, as a part of a Juvenile Diabetes Research Foundation (JDRF) patient advocate team, who worked successfully to convince the U.S. government to pass a $1.5 billion mandatory federal funding bill for an additional five years of Type 1 and Type 2 diabetes supplemental National Institutes of Health research funding. Mr. Klein served as the Chairman of the Governing Board of CIRM for the first seven years of its existence and was elected Chairman Emeritus in 2011.
Mr. Klein serves on the boards of directors of the International JDRF and the Global Security Institute, which is dedicated to reducing the global risk from nuclear weapons. He was appointed in 2007 to the Board of Directors of Genome Canada, a Canadian government genomic and proteomic research agency with $1.8 billion medical research portfolio. He was Co-chair of the Stem Cell and Regenerative Medicine Working Group of the Canada-California Strategic Innovation Partnership, the working group that initiated the Cancer Stem Cell Consortium in Canada. Mr. Klein has also served as the Vice-President of the Board of Directors of the State of the World Forum, an international organization focused on global economic development.
Mr. Klein is a member of both the California and the American Bar Association. He has a Bachelor of Arts in History with Honours from Stanford University and a Juris Doctorate from Stanford Law School. He is retired from the United States Air Force, having attained the rank of Captain.
Mr. Mark Lievonen is president of Aventis Pasteur Limited, the leading provider of vaccines in Canada. He has been with the company since 1983.
Prior to his appointment as president, Lievonen served as senior vice-president and general manager of the oncology business unit. In 2004, he was appointed to the board of directors of Calgary-based Oncolytics Biotech Inc., a research firm. He is also a member of the board of directors of BIOTECanada and served as Chair from 2000 to 2003.
Benjamin G. Neel, PhD, MD
Dr. Benjamin G. Neel is the Director of Research of the Princess Margaret Cancer Centre.
Previously, Neel was a Professor of Medicine at Harvard Medical School and Director of the Cancer Biology Program at the Beth Israel Deaconess Medical Center (BIDMC) in Boston. He also served as the Deputy Director for Basic Research, Hematology Division at BIDMC from 2003-2007. He was appointed to the William B. Castle Chair of Medicine at Harvard Medical School in 2006.
Neel is an internationally recognized expert in the field of cellular signal transduction, with particular expertise in the biology and regulation of protein- tyrosine phosphatases. He was the inaugural recipient of the Gertrude Elion Award of the American Association for Cancer Research. He has also received a Junior Faculty Research Award from the Leukemia and Lymphoma Society and a National Institutes for Health (NIH) MERIT award. He has served on study sections and ad hoc review panels for the NIH, American Cancer Society (Massachusetts Division), the California Tobacco and Breast Cancer Research Programs, the Canadian Cancer Society and the Starr foundation. He also was a long time member of the Scientific Advisory Board of Ceptyr, Inc, is a current member of the Scientific Advisory Board of Kolltan Pharmaceuticals, and is a consultant for Novartis, Inc.
Neel earned a PhD in Viral Oncology from Rockefeller University in 1982 and an MD from Cornell University Medical School the following year. He then completed internship and residency in Medicine at Beth Israel Hospital, and is board-certified in Internal Medicine.
John R. Riesenberger
Mr. John R. Riesenberger was most recently President of Consilium Partners, Inc., where he focused on process improvement and strategic, marketing and financial planning in the healthcare marketplace. Previously he worked in Fortune 500 pharmaceutical corporations, biotechnology firms and small, entrepreneurial firms, including positions as Corporate Vice President, Chief Commercial Officer at Mankind Corporation, Principal and Executive Vice-President of Shaw Science Partners, Inc. and Vice-President, Business Intelligence, Global Business Management at Pharmacia & Upjohn.
Riesenberger received his BS and MBA from Hofstra University and completed the International Senior Management Program at the Harvard Business School.
Mr. Allan Rock is the President and Vice-Chancellor of the University of Ottawa. A lawyer by training, Rock conducted a varied practice in civil, commercial and administrative litigation for over 20 years. He was a frequent lecturer to members of the Bar in Continuing Legal Education, and taught at the Osgoode Hall Law School of York University.
In 1993, he was elected as the Member of Parliament for Etobicoke-Centre and named Minister of Justice and Attorney General of Canada. In that capacity, he introduced significant improvements to the Criminal Code, the Canadian Human Rights Act and other federal legislation.
Rock became Minister of Health in 1997, where he spearheaded the creation of the Canadian Institutes of Health Research (CIHR) and more than doubled annual health research funding on a national scale. Subsequently, as Minister of Industry and Minister of Infrastructure, he introduced Canada’s innovation strategy, was responsible for Canada’s three granting councils and introduced legislation to create the Pierre Elliott Trudeau Foundation to promote applied research in the social sciences and the humanities.
Rock was appointed Ambassador of Canada to the United Nations in December 2003. As the voice of Canadians at the United Nations, Allan Rock was an outspoken advocate of human rights, human security and reforming the UN. Rock has received a number of awards including honorary degrees from the Law Society of Upper Canada (1996) and the University of Windsor (1997). He received the Meritas-Tabaret Distinguished Alumnus Award from the University of Ottawa in 2007.
Michael Sherar, PhD
Dr. Michael Sherar is President and CEO of Cancer Care Ontario. He is also a professor of Medical Biophysics at the University of Toronto.
From 2006 to 2011, Sherar served as Cancer Care Ontario’s Vice-President of Planning and Regional Programs. In this role, he led the development of regional cancer programs and the Ontario Cancer Plan, including capital planning for cancer services across the province. He previously served as regional vice-president, cancer services, London for Cancer Care Ontario, and vice-president, London Regional Cancer Program (LRCP), London Health Sciences Centre (LHSC).
Sherar received a BA in physics from Oxford University and a PhD in medical biophysics from the University of Toronto. In 2001, he was selected as one of Canada’s Top 40 under 40 for achievements in leadership.
Douglas John Paul Squires, PhD
Dr. Squires was CEO and Chairman of the Board of Biovail Corporation, Canada’s largest publically traded pharmaceutical company. During his tenure, he executed a major change in strategic direction of the company that culminated in the merger of Biovail with Valeant Pharmaceuticals in 2010.
Dr. Squires spent seven years with MDS Inc, a leading Canadian health sciences company. He was President of MDS Pharma Services, a top five global contract research organization that employed 4,000 employees in 41 sites in 22 countries. MDS Pharma Services provided drug discovery, preclinical and clinical development services to pharmaceutical and biotechnology companies and he was instrumental in developing strategic relationships with many MDS clients.
For more than 20 years, Dr. Squires worked with The Upjohn Company in many senior roles. He was President of The Upjohn Company of Canada from 1988 to 1989 prior to relocating to the corporate head office in Michigan. There, he ran both the infectious disease and critical care business groups that were responsible for R&D strategy, portfolio management and global product life cycle management. For seven years he was Regional Vice-President for the Asia Pacific Division of Upjohn and was accountable for the business operations of 12 countries that included seven manufacturing facilities, a generic company and four joint ventures. In 1994, he led Upjohn’s entry into China with the establishment of a pharmaceutical subsidiary and a state-of- the-art sterile manufacturing facility in Suzhou.
Dr. Squires received a B.Sc. from the University of Toronto and a PhD from the University of London. He was a postdoctoral fellow at the Institute of Cancer Research (London) and the Ontario Cancer Institute.
Ms. Leslee Thompson is President and CEO of Kingston General Hospital (KGH) and an assistant professor in the Faculty of Health Sciences at Queen’s University. Her 25-year healthcare career has spanned both the public and private sectors. She has held senior executive positions in leading organizations such as the University Health Network, Sunnybrook Health Sciences Centre, Cancer Care Ontario and Capital Health (Alberta). Most recently she was Vice-President, Health System Strategies for Canada with Medtronic, a global medical devices company.
Thompson is Vice-Chair of the Council of Academic Hospitals of Ontario (CAHO) and becomes Chair of CAHO in June 2013. She also sits on the Board of Directors for the Ontario Hospital Association, the Canadian Health Services Research Foundation and the Technology Evaluation in the Elderly Network a National Network Centre of Excellence funded by the Government of Canada, that focuses on improving care for seriously ill elderly patients and their families. Thompson served on the board of Shoppers Drug Mart for six years and is a certified Corporate Director (ICD.D)
Thompson earned her MBA from the University of Western Ontario, a Masters of Nursing degree from the University of Toronto, and a Bachelors of Nursing degree from Queen’s University.
Ms. Susan Thompson is currently the President of Susan Thompson Consulting, a privately held company specializing in providing consulting services to the Business Analysis profession.
Thompson has spent more than 35 years in the Software and Financial Services sectors, having held numerous senior management positions, notably at Bank of Montreal, IBM and 724 Solutions and CIBC.Throughout her career she has focused on Business/Systems Analysis,Project Management, User Interface Design, Process Engineering and Organizational Change Management. Her most recent position was Director of Business Analysis at CIBC, where she was responsible for streamlining methodology and processes, and establishing a Centre of Excellence for 600 Business Analysts in both business and technology. She retired from CIBC in May 2010.
As a Project Management Professional (PMP) and Certified Business Analyst Professional(CBAP), Thompson has been actively involved in many industry organizations and served on numerous advisory boards. Additionally, she is a member (and Chair – 2005) of Dragons Abreast – a dragon boat organization whose mission is to raise breast cancer awareness and encourage those with breast cancer to lead full and active lives.
Dave Williams, MD
Dr. Dave Williams is the President and CEO for Newmarket-based Southlake Regional Health Centre and Assistant Professor of Surgery at the University of Toronto. Prior to joining Southlake in July 2011, Williams was the Director of the McMaster Centre for Medical Robotics at St. Joseph’s Healthcare Hamilton and a Professor in the Department of Surgery of the Michael G. DeGroote School of Medicine. Dr. Williams also previously held the position of Chief Medical Officer of Quality and Safety at St. Joseph’s Healthcare Hamilton.
In 2007, Williams served as a NASA mission specialist on STS-118, the 119th space shuttle flight, the 22nd flight to the station, and the 20th flight for Endeavour. Williams took part in three of the four spacewalks; setting a Canadian record, he spent 17 hours and 47 minutes outside.
Williams’ many affiliations and awards include: Member of Sea Space (2010), Board Member for the Canadian Foundation for the International Space University (2009-2010), Board Member for the Centre for Surgical Invention and Innovation (2009), Science Ambassador for the Ontario Science Centre, Board Member for the Spinal Cord Injury Solutions Network (2008 - 2010), Member of the Minister’s Space Advisory Panel (2008-2010), Board Member for Canadian Warplane Heritage Museum (2008), A Fellowship in The Explorer’s Club (June 2008), the NASA Exceptional Service Award (June 2008), Honorary Board Member of Neuroscience Canada (May 2008), Member of the Canadian Commission for Antarctic Research, the NASA JSC Space and Life Sciences Directorate Special Professional Achievement Award for the implementation of the Automatic External Defibrillator Program that has saved several lives at the NASA Johnson Space Center(2003), the NASA Outstanding Leadership Medal (2002), Patron of the International Life Saving Federation (2002), and Rotary National Award for Space Achievement (2000).
Williams is a Fellow of the Royal College of Physicians and Surgeons and the College of Family Physicians of Canada. He is also a member of the College of Physicians of Ontario,the Ontario Medical Association, the Canadian Association of Emergency Physicians, the Undersea and Hyperbaric Medicine Society, and the Aerospace Medical Association.
Williams graduated from McGill University in Montreal, Quebec, with a Bachelor of Science, Major in Biology (1976). He obtained a Master of Science from the PhysiologyDepartment, a Doctorate of Medicine and a Master of Surgery from the Faculty of Medicine,McGill University (1983). He was awarded honorary degrees from the University of Saskatchewan, McGill University, the University of Wales, and Queen’s University.